EyePoint, Inc. (EYPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.58+0.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · EYPT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.8% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 17.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
EYPT — earnings miss
Dated 2026-08-05
Results of Operations and Financial Condition. On August 5, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto. Also on August 5, 2026, the Company posted an updated investor presentation on its website at www.eyepoint.bio. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
Why it matters: Achieving full enrollment is critical for the DME program's success and funding.
Supportive ifFull enrollment confirmed in the Phase 3 pivotal DME program.
Worry ifEnrollment remains below target levels past the Q3 2026 deadline.
Why it matters: This lawsuit's outcome may impact money and reputation.
Worry ifSettlement or resolution of the lawsuit is good for EyePoint.
Less concerning ifBad news or penalties related to the lawsuit.
Why it matters: This data helps us understand how well DURAVYU works for wet AMD. Good results could help it compete better.
Supportive ifThe LUCIA trial shows good results. This confirms that DURAVYU works well.
Worry ifThe LUCIA trial shows bad results. This raises doubts about the treatment's effectiveness.
Why it matters: This data will show how well DURAVYU works for wet AMD. Positive results could boost confidence in the product's market potential.
Supportive ifThe LUGANO trial shows good results. This means the treatment works well.
Worry ifThe LUGANO trial shows bad results. This raises doubts about the treatment's effectiveness.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$303 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $677 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,623 loss on $10,000 · 76.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The recent earnings miss raises worries. Signs of recovery would help investor trust.
Supportive ifThe next earnings report shows revenue growth or smaller losses from the last quarter.
Worry ifMore losses or more earnings misses are expected in the next financial reports.
Why it matters: Data from the LUGANO and LUCIA trials will show how well DURAVYU works for wet AMD.
Supportive ifTopline data from the wet AMD trials is released starting mid-2026.
Worry ifData is late or shows bad results.
Why it matters: Updates on cash runway will show financial health and if they can fund trials.
Worry ifCash and investments are above $180 million. This shows a good runway into Q4 2027.
Less concerning ifCash and investments are below $150 million. This raises worries about funding future work.
Why it matters: If revenue growth picks up, it may help EyePoint's performance. This could signal a better environment for the company.
Supportive ifSector revenue growth increases back toward 10% or higher.
Worry ifSector revenue growth continues to slow or stays below 10%.
Why it matters: Updates on enrollment will show interest in DURAVYU for DME. Strong enrollment means good market potential.
Supportive ifEnrollment in COMO and CAPRI trials is done early. This shows strong interest.
Worry ifEnrollment in COMO and CAPRI trials is below expectations. This shows weak interest.
Why it matters: Progress in this program is key for EyePoint's future. It affects investor confidence.
Supportive ifThey announced good results for the Phase 3 wet AMD program.
Worry ifNo updates or negative results from the Phase 3 wet AMD program.
Why it matters: Results from the DME trials will show DURAVYU's effectiveness in a significant market. Positive results can enhance growth prospects.
Supportive ifData from the COMO and CAPRI trials shows strong results in treating DME.
Worry ifData from the COMO and CAPRI trials shows treatment is not effective or has safety issues.
Why it matters: LUCIA data will confirm or challenge DURAVYU's potential as a treatment for wet AMD. Positive results could support FDA approval plans.
Supportive ifThe LUCIA trial shows it is not worse than aflibercept. The p-value is below 0.05.
Worry ifLUCIA data does not show it is not worse than aflibercept. There are safety concerns.
Why it matters: These trials will show how well DURAVYU works for diabetic macular edema. Good results could help in the market.
Supportive ifThe COMO and CAPRI trials show a big gain in BCVA over aflibercept.
Worry ifThe COMO and CAPRI trials show no big improvement. There are safety concerns.